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The National Cancer Institute has received the final conclusions and recom-
mendations ofa 16-member panel that examined the issues and state ofthe art of
breast cancer screening. The Panel, which met September 14, 15 and 16 at
Bethesda, Md., consisted ofclinicians, scientists andlaypeople. Itwaschairedby
Samuel Thier, M.D., professor and chairman of the Department of Internal
Medicine, Yale University.
Much ofthe discussion centered on the use ofmammography in routine breast
cancer screening.
The Panel concluded that scientific evidence of the benefit of X-ray mammo-
graphy wasprovided inastudybytheHealthInsurancePlan (HIP)ofGreaterNew
York, conducted in the 1960s. Theyagreedthatbenefit, as measuredbymortality,
was established for women age 50 and over and that this benefit was provided
through combined use ofphysical examination and mammography. No scientific
evidence is available to determine the individual contribution ofeach method. No
similar evidence of benefit to women under 50 could be established.
Throughout the proceedings the Panel was careful to emphasize the difference
betweentheuseofmammography asascreeningtoolandasadiagnostictechnique.
The value of mammography as used in diagnosis for evaluating symptoms or
clinical signs ofbreast cancer, such as thepresence ofalump, swelling, discharge,
dimpling, thickening or other abnormality in the breast, has not been questioned.
Panel members acknowledged that mammography has improved markedly in
recent years, detecting smaller and presumably earliercancers, and that radiation
dosage from the procedure has been reduced greatly. Nonetheless, they accepted
thepresumedriskofexposuretoradiationfrommammographythatwasoutlinedin
a report submitted in March 1977, byDr. ArthurC. Upton, then head ofan adhoc
working group studying the risk of radiation exposure. That report stated that
current evidence strongly suggests adirectlinearrelationshipbetween the amount
ofradiation exposure and the risk ofdeveloping cancer. Itplaced the presumptive
increased risk from exposure to the breast at less than 1 percent per rad. This
implies that a mammogram using current low-dose techniques would increase a
woman's presumed lifetime risk ofbreast cancer from an average natural level of
about7percent to alevelofless than7.07percentfollowingmammography.
The National Cancer Institute has accepted these findings and, based upon the
Panel's recommendations, has instructed directors ofthe 27 Breast CancerDetec-
tionDemonstration Projects to restrict the routine use ofmammography in annual
screening to women 50 years ofage and older. Women ages 40 through 49will be
offeredmammographyinscreeningonlyiftheyhaveapriorhistoryofbreastcancer
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oriftheirmotheror sister(s)havehadbreastcancer. Theuseofmammographyfor
women age 35 through 39willberestrictedtothosewithahistoryofbreastcancer.
Exceptfor women ages 35 through 39, theseguidelinesareidentical tothoseunder
which the BCDDP has operated since May 1977.
The projects, initiated in 1973, are cosponsored by the NCI and the American
Cancer Society. They have enroiled280,000women ages 35 through 74inavolun-
tary screening program. Medical history, physical examination, X-ray mammo-
graphy, thermography and the teaching of breast self-examination are used to
demonstrate methods for the early detection of breast cancer.
The consensus group concluded that although there is no known hannful effect
from thermography, there are no scientific data supporting its value as a routine
breast cancer screening technique under present conditions ofgeneral use. They
strongly suggested that research be carried out to improve thermographic tech-
niques and to determine its role in screening. It was recommended that thermo-
graphy be discontinued as part ofthe routine BCDDP screeningprocess except in
those centers where proficiency is available tojustify furtherclinicalinvestigation
under appropriate research design.
The NCI will discuss the use of thermography with each project director to
detennine which centers mightprovide valuable informationbycontinuingits use.
Until these determinations are made, all centers will continue to offerthermogra-
phy as part of the routine screening process.
Panel members concluded the BCDDPs may have an ethical obligation to
continue to offermammography towomen under50enrolled intheprogram, ifitis
madecleartothemthrough informed consentthatthebenefithas notbeenproved,
that there is presumed risk, and that the panel does not recommend its routine use
for this age group.
TheNCIhasmadenofinaldetermination inthismatter. Anewinformedconsent
form is being developed that will reflect these concerns. Until it iscompleted, the
BCDDPs have been instructed to continue screening with mammography only
those women designated by the panel or those whose personal physicians have
submitted written requests for mammography. The new informed consent form
alsowill includethe radiationdosage received. Thisinformationwillbesupplied at
each project and will be updated as appropriate. Inclusion ofdosage information
was recommended by the panel.
Data on the breast cancer detection rates of the BCDDPs were provided in a
reportfrom the WorkingGroup toReview theNCI/ACS BreastCancerDetection
Demonstration Projects, chaired by Dr. Oliver Beahrs of the Mayo Clinic. The
Pathology Review Committee of the Beahrs group had reviewed 506 cases of
"minimal" cancers (less than 1 centimeter in size, or papillary or intraductal
cellular proliferations). Of these, they concluded that 66 cases that had been
interpreted previously as cancerous should be reclassified as benign. (This figure
later was revised to 64 cases.) They designated an additional 22 cases as
"borderline," becauseagreementcouldnotbereached onwhetherthelesionswere
benign or malignant. The Panel recommended that in these instances the women
involved should be notified that their cases had been reinterpreted.
Topursue these developments, the NCIbegan animmediate review ofthe cases
inquestionandfoundthatthePathology ReviewCommittee maynothavereceived
consistently all the pathology slides used by the hospitalpathologist inmaking his
diagnosis. Forexample, when the entire tumorwas removedduringbiopsy, tissue
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samples obtainedfollowing subsequent surgery contained nomalignanttissue. Ina
number ofcases a two stage procedure-biopsy during one operation and surgery
as a later, separate procedure-was performed. In many such cases, the original
pathologist considered the case to be borderline and consulted several otherpath-
ologists before treatment decisions were made. Often the womanwas informed of
the difficulty in making a pathological assessment, and she was involved in the
decision to go ahead with surgery. Therefore, it has become clear that in most
instances the original pathologist recognized difficulty in assessing the lesion; that
interpretation may have depended critically on the particular slide or slides
examined; that differences ofopinion about these lesions may not be uncommon,
and that a final assessment may be fraught with considerable uncertainty.
Theprojectdirectorshavebeenaskedtoreviewthematerials senttotheBCDDP
Working Group (Beahrs group), to obtain additional slides not available to the
Review Committee, to discuss the diagnosis, treatment and other pertinent
information-such as medical history-with the project pathologist, hospital
pathologist and personal physician, and to submit to the Beahrs group all
informationthatmightclarifythefindingsofthePathologyReviewCommittee. The
entire Beahrs group has been asked toexaminethisadditionalinformationandwill
submit a final report on its findings in mid-November.
It is expected that the number of cases in which reclassification as benign or
borderline persists will be lower than that first reported by the Beahrs group. A
procedurefornotifyingthewomenwhosecases maydeservetoremainreclassified
after further review is being developed by the NCI, the project directors, and the
collaborating physicians.
Itwas recommendedthatthosewomenintheBCDDPsinwhomcancerhasbeen
detected befollowedtoprovidevaluable scientific information. Panelists couldnot
reach a consensus on whetherthose women in whom no cancers have been found
also should be followed after conclusion of the screening program.
TheNCI recognizesthatfollowupstudiesonwomenwithcancer, particularlyon
the "minimal" type, can provide valuable insight into the progression of breast
cancer. TheInstitutewilldevelopprocedures tofollowwomenwhosecancerswere
diagnosed through BCDDP screening. Followup of "normal" screenees is under
study.
ThePanelconcluded thatthere is aneed forquality controlofthe screeningpro-
cedures, including physical examination, and of the pathological review. They
recommended that concurrent pathological review by consulting pathologists of
"minimal" lesions beperformedroutinelybefore treatment isinstituted(two-stage
procedure).
The National Cancer Institute will work out details with BCDDP project direc-
tors to implement this recommendation.
Before making its recommendations, the panel heard presentations on the
benefits and risks ofroutine breast cancerscreeningofsymptom-free womenfrom
four groups ofscientists who have studied the issue and from otherprofessionals
and concerned members of the public.
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